Temasek Holdings Private Ltd Has $44.48 Million Position in Guardant Health, Inc. $GH

Key Points

• Temasek Holdings Private Ltd reduced its stake in Guardant Health by 33.2%, selling 517,882 shares and now owns approximately 1,044,097 shares valued at $44.5 million.
• Analysts have issued positive updates, with several firms raising their price targets for Guardant Health, with Scotiabank setting a new target of $60.00 and establishing a "sector outperform" rating.
• Guardant Health reported a revenue increase of 31% year-over-year in its latest earnings, with a quarterly revenue of $232.09 million, which surpassed analysts' expectations.

Temasek Holdings Private Ltd cut its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 33.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,044,097 shares of the company's stock after selling 517,882 shares during the period. Temasek Holdings Private Ltd owned 0.84% of Guardant Health worth $44,479,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. increased its position in shares of Guardant Health by 0.3% in the first quarter. American Century Companies Inc. now owns 104,206 shares of the company's stock worth $4,439,000 after acquiring an additional 282 shares in the last quarter. HighTower Advisors LLC grew its position in Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company's stock valued at $2,177,000 after acquiring an additional 469 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Guardant Health by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock valued at $112,000 after purchasing an additional 537 shares in the last quarter. GF Fund Management CO. LTD. grew its stake in shares of Guardant Health by 22.0% during the first quarter. GF Fund Management CO. LTD. now owns 3,164 shares of the company's stock valued at $135,000 after acquiring an additional 570 shares in the last quarter. Finally, Xponance Inc. grew its stake in Guardant Health by 6.8% during the 1st quarter. Xponance Inc. now owns 9,116 shares of the company's stock valued at $388,000 after purchasing an additional 582 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on GH shares. Mizuho raised their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Friday, June 13th. Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research note on Monday, July 14th. Scotiabank increased their price objective on Guardant Health from $57.00 to $60.00 and gave the stock a "sector outperform" rating in a report on Thursday, July 31st. BTIG Research boosted their price target on Guardant Health from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Thursday, September 4th. Finally, Raymond James Financial upped their target price on Guardant Health from $59.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $58.24.

Guardant Health Trading Down 4.8%

Guardant Health stock traded down $2.87 on Wednesday, reaching $56.57. 2,438,931 shares of the stock were exchanged, compared to its average volume of 2,393,922. Guardant Health, Inc. has a twelve month low of $20.14 and a twelve month high of $68.00. The stock has a market cap of $7.05 billion, a PE ratio of -16.89 and a beta of 1.45. The firm has a fifty day moving average price of $53.46 and a two-hundred day moving average price of $47.39.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.08. The business had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. The business's revenue for the quarter was up 31.0% on a year-over-year basis. During the same period last year, the company earned ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. Equities analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Activity at Guardant Health

In related news, Director Ian T. Clark sold 6,672 shares of Guardant Health stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total value of $322,791.36. Following the sale, the director owned 9,851 shares of the company's stock, valued at approximately $476,591.38. This trade represents a 40.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Musa Tariq sold 3,213 shares of the company's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $49.47, for a total value of $158,947.11. Following the transaction, the director directly owned 7,190 shares of the company's stock, valued at approximately $355,689.30. This trade represents a 30.89% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,258 shares of company stock valued at $5,880,919 over the last three months. Insiders own 6.10% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.